95% Of Us Have Epstein-Barr Virus (EBV), What Can We DO?
Epstein-Barr Virus (EBV), also known as the human herpesvirus 4, is one of the eight viruses in the herpes family and the most common virus present in humans. It is best known as the cause of infectious mononucleosis (glandular fever) which is often referred to as ‘the kissing disease’. It is estimated that most people, roughly 90-95% of the world’s population have been infected with Epstein-Barr Virus (EBV) at some point in their lives.
Fortunately, for most of people the virus stays dormant and doesn’t present with any noticeable symptoms however this does not mean the body isn’t impacted by the infection. Furthermore, in some individuals the Epstein-Barr Virus (EBV) infection can reactivate resulting in the serious dreaded symptoms/conditions such as chronic fatigue syndrome (CFS), autoimmune disease, fever, enlarged spleen and so on.
What is the Epstein Barr Virus?
Epstein-Barr Virus (EBV) is spread through intimate contact – meaning bodily fluids, primarily saliva, as well as blood and semen. Hence the commonly called kissing disease. Regardless if the Epstein-Barr Virus (EBV) is active or dormant, it can still be spread to others thus resulting in its high prevalence.
Consequentially, as it is spread through bodily fluids additional to kissing and sex, it can be spread by sharing drinks or drinking from the same glass, sharing a toothbrush, organ transplant or blood transfusions.
Epstein-Barr Virus (EBV) is a member of the herpes family and as previously mentioned the infection can often be symptom free.
When our system is attacked by a viral infection, our bodies respond by commanding our B cells within our immune system to crank out antibodies and battle the invaders. However, when an EBV infection occurs, something unusual happens. The Epstein-Barr Virus (EBV) invades the B cells themselves and takes over the control of their functions. Circulating B cells spread the infection throughout the entire system particularly the liver, spleen and peripheral lymph nodes.
The herpes viridae family include: herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, Epstein-Barr virus (EBV or HHV-4), cytomegalovirus (HHV-5) among several others.
A characteristic of the herpes viridae family is that once you’ve have it, the virus no longer leaves the host after the first infection and nests in a cell type of the organism causing a so-called latent infection. This occurs in a variable time depending on the type of virus and the sensitivity of the host. From this latency state of the Epstein-Barr Virus (EBV) can reactivate, even after many years, resulting in a recurrence of the disease.
The stimuli that induce the re-activation of Epstein-Barr Virus (EBV) viral activity can be temperature changes, trauma, stress and especially changes in the immune defense status of the body such as immunodeficiency. For a small amount of people, the Epstein-Barr Virus (EBV) can actually remain chronically active known as chronic active Epstein Barr virus (CAEBV).
Epstein-Barr Virus (EBV) is responsible for productive lytic infections, which after a period of time depending on the reactivity of the infected person, turns into a latent infection. The latency site is different for each herpes virus, but they reside in areas of the body that are protected from constant attack of the immune system, which makes the eradication of these viruses such as Epstein-Barr Virus (EBV) from the infected person extremely difficult.
Furthermore, research has shown that Epstein-Barr Virus (EBV) does not simply cause glandular fever (infectious mononucleosis) but several other serious diseases. It was discovered that a protein produced by the Epstein-Barr Virus (EBV) interacts with a number of genes – associated with these diseases. Through these gene mutations the function of the immune system is altered, speculated to primarily affect B cells which produce the antibodies in response to infection and viruses.
Diseases found to be linked with Epstein-Barr Virus (EBV) include;
- Systemic lupus erythematosus
- Type 1 diabetes
- Celiac disease
- Multiple sclerosis
- Inflammatory bowel disease
- Ulcerative colitis
- Crohn’s disease
- Guillain-Barre syndrome
- Rheumatoid arthritis
Additionally, Epstein-Barr Virus (EBV) is estimated to cause over 200,000 cases of cancer worldwide, principally lymphomas (Burkitt’s lymphoma, Hodgkin’s lymphoma), nasopharyngeal cancer and some stomach cancers.
Signs & symptoms of Epstein-Barr Virus (EBV)
Common symptoms of latent and active Epstein-Barr virus include:
Fatigue, sometimes severe and often the most common symptom (chronic fatigue syndrome). Chronic fatigue syndrome has various different names such as: epidemic neuromyasthenia, myalgic encephalomyelitis, postviral fatigue syndrome, chronic fatigue and immune system dysfunction syndrome.
Some aliments associated with EBV:
- Adrenal and thyroid disease
- Anxiety and depression
- Autoimmune disease
- Brain fog
- Cardiovascular disease
- Disc prolapse
- Disease of the digestive tract
- Eating disorders
- Easy bruising
- Gall stones
- Ligament and tendon injuries
- Menstrual problems
- Peripheral vascular disease
- Stretch marks
- Viral, fungal and yeast infections
What are the treatment goals?
Due to how ubiquitous Epstein-Barr Virus (EBV) infection is and the fact that there is no specific and effective treatment available, it is often ignored by the medical industry, or at least its impact on health for many people has been grossly underestimated.
There is no permanent cure for Epstein-Barr Virus (EBV), and therefore treatments should rather focus on returning the body to homeostasis by reducing the EBV infection and in turn shutting down the viral activity.
- suppress and eliminate the Epstein-Barr Virus (EBV) from the body, and
- create an environment in the body where the virus can’t thrive.
Ozone plays a fundamental role in the treatment of multifactorial infectious disease states such as Epstein-Barr Virus (EBV) infection or chronic fatigue associated with EBV; this is due to its direct and indirect mechanism of action:
- Anti-microbial – antibacterial, antifungal and most importantly its antiviral effects (ozone damages the viral capsid and upsets the reproductive cycle by disrupting the virus-to-cell contact with peroxidation)
- Ozone therapy activates the immune system. O3 increases the production of interferon and the greatest output of tumor necrosis factor and interleukin-2. The production of interleukin-2 launches an entire cascade of subsequent immunological reactions.
- Ozone therapy decreases inflammation
- Ozone activates the citric acid cycle by enhancing oxidative carboxylation of pyruvate, stimulating production of ATP (which is energy).
- Ozone leads to an increase in the amount of oxygen released to the tissues, resulting in improved circulation.
- Ozone therapy activates Nrf2 pathway (is the master regulator of the cellular antioxidant response)
- Ozone therapy causes an increase in the red blood cell glycolysis rate.
- Ozone increases our most potent radical scavenger and cell wall protectors: glutathione peroxidase, catalase and superoxide dismutase.
To treat Epstein-Barr Virus (EBV) infection ozone is administered through various different routes and with variable therapeutic doses of ozone. It is administered in the form of gas. Ozone represents an unstable molecule characterized by 3 atoms of oxygen. Ozone gas comes in contact with fluid within the body (mainly water) or organic matter (cells, bacteria, viruses, stool, blood…) and prompt Ozonolysis takes place. This process happens in fractions of secondsand the reaction leads to the formation of: Ozonides aldehydes and Peroxides hydrogen peroxide (H2O2).
Ozonides aldehydes and hydrogen peroxide (H2O2) induce a mild oxidative stress at cellular level. H2O2 is quickly reduced to H2O (water) and O2 (oxygen) by free anti-oxidants in the blood and cells. The half-life of H2O2 is literally 60 seconds and yet its intracellular concentration is critical in order to activate the biochemical pathways. Thus it causes an oxidative reaction, which transforms into second messengers with long lasting action. No damage to healthy cells occurs during this process.
Ozone and Ozonites destroy viruses by diffusing through the protein coat into the nucleic acid core, resulting in damage of the viral RNA. Unlike healthy cells, which posses’ complex enzyme systems (superoxide dismutase, catalase, peroxidase) viruses have no protections against oxidative stress, therefore making viruses such as Epstein-Barr Virus (EBV) vulnerable to ozone.
In March 2019 a new case report was published about the effects of ozone therapy in meningoencephalitis and chronic fatigue.
The case report discussed two patients, one young boy diagnosed with acute meningoencephalitis, as well as positive serology results for cytomegalovirus (CMV) and Epstein Barr Virus. After intravenous antibiotic and antiviral therapy for the meningoencephalitis the patient was diagnosed with post-infectious CFS (due to the positive Epstein-Barr Virus (EBV) infection). The patient was then treated with ozone therapy, rectal insufflation at twice weekly for 4 weeks continued to weekly treatments for a further 4 weeks; this was accompanied with nutritional/herbal supplementation. The patient went into complete remission of symptoms associated with chronic fatigue and Epstein-Barr Virus.
The second patient they treated was a world champion athlete for post-infectious CFS with a similar clinical picture of previous toxoplasmosis infection and asymptomatic assessed mononucleosis (EBV). The patient was also treated with rectal ozone therapy and they observed a complete remission of the CFS neurological and functional symptoms of post infection. The ozone therapy was performed throughout the patients ongoing training until remission was completed. One year later the athlete went on to win a gold medal in the World Champion title.
In this 2019 case report it was concluded that ozone therapy is the only effective therapeutic treatment to restore and alleviate the symptoms from post infectious meningoencephalitis syndromes, chronic fatigue from both infectious (Epstein-Barr Virus (EBV)) and non-infectious disease states.
What do you do after reducing the EBV with ozone?
Reducing the Epstein-Barr Virus (EBV) infection with regular rectal and vaginal ozone treatments is the first and most important treatment. This includes hygiene with ozone water and ozone oils for topical application.
Once this has been implemented the next step is restoring the body’s immune system. Being immunocompromised is a major risk factor for reactivating EBV infection.
How do we ensure our immune system is functioning properly?
- Clean diet and adequate nutrition – reducing pro-inflammatory foods and increasing nutrient dense foods. Eliminating any trigger or immunosuppressive foods including: gluten, diary, allergens, intolerances, sugar etc.
- Hydration – important to drink at least 2 liters every day
- A healthy gut microbiome – healing the gut is a priority for anyone dealing with EBV infections. See the Leaky Gut protocol for Ozone which includes supplement recommendation to discuss with your nutritionist of naturopath.
- Reduce toxic burden – toxins suppress the function of the immune system. Therefore, it is important to decrease the critical toxic load by eliminating petrochemicals, fragrances, pesticides and fungicides, chemical agents and medication.
- Optimizing detoxification pathways – this includes supporting the liver/kidneys and providing the appropriate co-factors for phase 1 and 2 detox.
- Improving sleep habits – this is essential as the repair and detoxification occurs while you sleep. Ensuring adequate sleep hygiene. (no synthetics, emf, light pollution, outgassing mattress, a.s.o.)
- Reduce stress – as this is a major cause of immune system dysfunction, it could be what triggered the activation of Epstein-Barr Virus (EBV) and what can also reactive it.
- Supplementation – herbal and nutritional supplements are required to support the immune system and the body’s ability to regain homeostasis.
Includes: 1 x Ozone Generator with 5 year warranty, 6 OZONE OILS, 1.5m silicon hose, 1 x International power supply and plugs, 1 Flow Regulator (medical or industrial), 2 x Ozone Insufflation Bags, 10 x Ozone Catheters, 1 x Limb Ozone Bag with in/outlet, 1 x MnO3 Ozone Destruct Unit, 2 x 60ml Syringes, 6 x Luerlock connectors AND MORE!
Bocci, V. (n.d.). Ozonization of Blood for the Therapy of Viral Diseases and Immunodeficiencies . A Hypothesis, 30–34.
Bocci, V. (1996). Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. Journal of Biological Regulators and Homeostatic Agents.
Burleson, G. R., Murray, T. M., Burleson, G. R., Murray, T. M., & Pollard, M. (1975). Inactivation of Viruses and Bacteria by Ozone , With and Without Sonication Inactivation of Viruses and Bacteria by Ozone , With and Without Sonication.
Carpendale, M. T. F., & Frceberg, J. K. (1991). Ozone inactivates H IV at noncytotoxic concentrations, 16, 281–292.
Clavo, B., Pérez, J. L., López, L., Suárez, G., Lloret, M., Rodríguez, V., … Robaina, F. (2004). Ozone Therapy for Tumor Oxygenation: a Pilot Study. Evidence-Based Complementary and Alternative Medicine, 1(1), 93–98. https://doi.org/10.1093/ecam/neh009
Cohen, J. I. (2009). Optimal treatment for chronic active Epstein-Barr virus disease: Editorial. Pediatric Transplantation, 13(4), 393–396. https://doi.org/10.1111/j.1399-3046.2008.01095.x
Elvis, A. M., & Ekta, J. S. (2011). Ozone therapy : A clinical review,2(1), 66–70. https://doi.org/10.4103/0976-9668.82319
Harley, J. B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., … Weirauch, M. T. (2018). Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genetics, 50(5), 699–707. https://doi.org/10.1038/s41588-018-0102-3
Hess, R. D. (2004). Routine Epstein-Barr virus diagnostics from the laboratory perspective: Still challenging after 35 years. Journal of Clinical Microbiology, 42(8), 3381–3387. https://doi.org/10.1128/JCM.42.8.3381-3387.2004
Landais, E., Saulquin, X., & Houssaint, E. (2005). The human T cell immune response to Epstein-Barr virus. International Journal of Developmental Biology, 49(2–3 SPEC. ISS.), 285–292. https://doi.org/10.1387/ijdb.041947el
Martínez-Sánchez, G., Delgado-Roche, L., Díaz-Batista, A., Pérez-Davison, G., & Re, L. (2012). Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. European Journal of Pharmacology,691(1–3), 156–162. https://doi.org/10.1016/j.ejphar.2012.07.010
Mawsouf, M. N., Tanbouli, T. T., Mawsouf, M. N., & Tanbouli, T. T. (2016). Ozone : Science & Engineering The Journal of the International Ozone Association Ozone Therapy in Patients with Viral Hepatitis C : Ten Years ’ Experience Ozone Therapy in Patients with Viral Hepatitis C : Ten Years ’ Experience, 9512(June). https://doi.org/10.1080/01919512.2012.720161
Miyamura, T., Chayama, K., Wada, T., Yamaguchi, K., Yamashita, N., Ishida, T., … Morishima, T. (2008). Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation. Pediatric Transplantation, 12(5), 588–592. https://doi.org/10.1111/j.1399-3046.2007.00873.x
Morelli, L., Bramani, S. C., & Morelli, F. C. (2019). Oxygen-ozone therapy in meningoencephalitis and chronic fatigue syndrome. Treatment in the field of competitive sports: case report. Ozone Therapy, 4(1). https://doi.org/10.4081/ozone.2019.8176
Ms, J. D., Menéndez-cepero, S., Macías-abraham, C., & Ms, L. F. (2017). Systemic Ozone Therapy by Rectal Insufflation for Immunoglobulin A Deficiency, 29–35.
Nogales, C. G., Ferrari, P. H., Kantorovich, E. O., & Lage-Marques, J. (2008). Ozone therapy in medicine and dentistry. Journal of Contemporary Dental Practice, 9(4), 1–9.
Ozler, M., Akay, C., Oter, S., Ay, H., & Korkmaz, A. (2016). Similarities and differences of hyperbaric oxygen and medical ozone applications, 5762(June). https://doi.org/10.3109/10715762.2011.627331
Pender, M. P. (2012). CD8+ t-cell deficiency, epstein-barr virus infection, vitamin d deficiency, and steps to autoimmunity: A unifying hypothesis. Autoimmune Diseases, 1(1). https://doi.org/10.1155/2012/189096
Sagai, M., & Bocci, V. (2011). Mechanisms of Action Involved in Ozone Therapy : Is healing induced via a mild oxidative stress ?, 1–18.
Smith, A. J., Oertle, J., Warren, D., & Prato, D. (2015). Ozone Therapy : A Critical Physiological and Diverse Clinical Evaluation with Regard to Immune Modulation , Anti-Infectious Properties , Anti-Cancer Potential , and Impact on Anti-Oxidant Enzymes, (August), 37–48.
Uchakin, P. N., Parish, D. C., Dane, F. C., Uchakina, O. N., Scheetz, A. P., Agarwal, N. K., & Smith, B. E. (2011). Fatigue in Medical Residents Leads to Reactivation of Herpes Virus Latency. Interdisciplinary Perspectives on Infectious Diseases, 2011, 1–7. https://doi.org/10.1155/2011/571340
White, P. D. (2007). What Causes Prolonged Fatigue after Infectious Mononucleosis—and Does It Tell Us Anything about Chronic Fatigue Syndrome? The Journal of Infectious Diseases, 196(1), 4–5. https://doi.org/10.1086/518615